UB Paderborn / Katalog / Suche / in CDI

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

The lancet oncology, 2014-08, Vol.15 (9), p.1019-1026

2014

Volltextzugriff (PDF)

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism

The Journal of clinical investigation, 2007-11, Vol.117 (11), p.3583-3592

2007

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2015-10, Vol.33 (30), p.3401-3408

2015

Volltextzugriff (PDF)

Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations

International journal of clinical pharmacology and therapeutics, 2013-04, Vol.51 (4), p.338

2013

Volltextzugriff (PDF)

Stable isotope‐labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults

British journal of clinical pharmacology, 2016-02, Vol.81 (2), p.235-245

2016

Volltextzugriff (PDF)

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Clinical cancer research, 2013-08, Vol.19 (15), p.4262-4272

2013

Volltextzugriff (PDF)

Abiraterone Acetate to Lower Androgens in Women With Classic 21-Hydroxylase Deficiency

The journal of clinical endocrinology and metabolism, 2014-08, Vol.99 (8), p.2763-2770

2014

Volltextzugriff (PDF)

In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity

Drug metabolism and disposition, 2016-10, Vol.44 (10), p.1682-1691

2016

Volltextzugriff (PDF)

Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan

JNCI : Journal of the National Cancer Institute, 2000-10, Vol.92 (20), p.1651-1656

2000

Volltextzugriff (PDF)

Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer

European urology, 2016-11, Vol.70 (5), p.718-721

2016

Volltextzugriff (PDF)

Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects

Journal of opioid management, 2013-07, Vol.9 (4), p.291

2013

Volltextzugriff (PDF)

Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4

Drug metabolism and disposition, 2005-07, Vol.33 (7), p.892

2005

Volltextzugriff (PDF)

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir

The Journal of pharmacology and experimental therapeutics, 2003-02, Vol.304 (2), p.596

2003

Volltextzugriff (PDF)

Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene

Molecular and Cellular Biology, 2001-08, Vol.21 (16), p.5471-5477

2001

Volltextzugriff (PDF)

Population Pharmacokinetics of Tapentadol Immediate Release (IR) in Healthy Subjects and Patients with Moderate or Severe Pain

Clinical pharmacokinetics, 2010-10, Vol.49 (10), p.671-682

2010

Volltextzugriff (PDF)

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure

The Journal of clinical investigation, 1999-11, Vol.104 (10), p.1441-1447

1999

Volltextzugriff (PDF)

Dose-response relationship after single oral dose administrations of morphine and oxycodone using laser-evoked potentials on UVB- and capsaicin-irritated skin in healthy male subjects

Pain (Amsterdam), 2012-08, Vol.153 (8), p.1648-1656

2012

Volltextzugriff (PDF)

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

AIDS (London), 2002-11, Vol.16 (17), p.2295-2301

2002

Volltextzugriff (PDF)

Limited Oral Bioavailability and Active Epithelial Excretion of Paclitaxel (Taxol) Caused by P-glycoprotein in the Intestine

Proceedings of the National Academy of Sciences - PNAS, 1997-03, Vol.94 (5), p.2031-2035

1997

Volltextzugriff (PDF)

Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open-Label, Crossover, Drug-Drug Interaction Studies

Pharmacotherapy, 2010-01, Vol.30 (1), p.25-34

2010

Volltextzugriff (PDF)

Interactions between P‐glycoprotein substrates and other cationic drugs at the hepatic excretory level

British journal of pharmacology, 1998-02, Vol.123 (3), p.361-370

1998

Volltextzugriff (PDF)

Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors

AIDS (London), 2000-02, Vol.14 (3), p.237-242

2000

Volltextzugriff (PDF)

P-Glycoprotein Limits Oral Availability, Brain, and Fetal Penetration of Saquinavir Even with High Doses of Ritonavir

Molecular pharmacology, 2001-04, Vol.59 (4), p.806-813

2001

Volltextzugriff (PDF)

Predicting Oral Clearance in Humans: How Close Can We Get with Allometry?

Clinical pharmacokinetics, 2008, Vol.47 (1), p.35-45

2008

Volltextzugriff (PDF)

Towards a Better Prediction of Peak Concentration, Volume of Distribution and Half-Life after Oral Drug Administration in Man, Using Allometry

Clinical pharmacokinetics, 2011-05, Vol.50 (5), p.307-318

2011

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations

Stable isotope‐labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Abiraterone Acetate to Lower Androgens in Women With Classic 21-Hydroxylase Deficiency

In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity

Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan

Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer

Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects

Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir

Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene

Population Pharmacokinetics of Tapentadol Immediate Release (IR) in Healthy Subjects and Patients with Moderate or Severe Pain

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure

Dose-response relationship after single oral dose administrations of morphine and oxycodone using laser-evoked potentials on UVB- and capsaicin-irritated skin in healthy male subjects

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

Limited Oral Bioavailability and Active Epithelial Excretion of Paclitaxel (Taxol) Caused by P-glycoprotein in the Intestine

Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open-Label, Crossover, Drug-Drug Interaction Studies

Interactions between P‐glycoprotein substrates and other cationic drugs at the hepatic excretory level

Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors

P-Glycoprotein Limits Oral Availability, Brain, and Fetal Penetration of Saquinavir Even with High Doses of Ritonavir

Predicting Oral Clearance in Humans: How Close Can We Get with Allometry?

Towards a Better Prediction of Peak Concentration, Volume of Distribution and Half-Life after Oral Drug Administration in Man, Using Allometry

Suchergebnisse filtern